LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the presentation of four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place in Munich, Germany from October 10-13, 2026. The posters highlight new preclinical data describing LB-102’s differentiated mechanism of action, the pivotal program of LB-102 in schizophrenia (NOVA-2 and NOVA-3), the ongoing late-stage development of LB-102 in bipolar depression (ILLUMINATE-1), and a previously reported analysis of LB-102’s impact on cognitive performance from the Phase 2 NOVA-1 trial in schizophrenia.